At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Optimized Treatment That Includes or Omits NRTIs Trial: A Randomized Strategy Study for HIV-1-Infected Treatment-Experienced Subjects Using the cPSS to Select an Effective Regimen
In Brief
A Phase 3 clinical trial evaluating Enfuvirtide, Raltegravir, and 4 other interventions for HIV Infections. Completed, enrolled 517 participants across 64 sites in 2 countries.
Detailed Summary
The goal of anti-HIV therapy is to prevent HIV from replicating. Long-term control of HIV requires at least two anti-HIV drugs that are active against the virus. Drug resistance is a problem for many treatment-experienced, HIV-infected people. The purpose of this study was to determine the benefit of adding a nucleoside reverse transcriptase inhibitor (NRTI) to a new anti-HIV drug regimen for the suppression of HIV.
Study Details
Timeline
Interventions
90mg subcutaneously twice daily
400 mg twice daily
Two 300-mg tablets twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
Two 250-mg capsules twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
Two 100-mg tablets twice daily
Dosage dependent on regimen in which maraviroc is included